Yesterday, the Alzheimer community woke up to another breaking news. Aducanumab (Biogen/Eisai) has been brought back from the dead, and Biogen plans to file a Biologics License Application (BLA) in early 2020. This is based on a new analysis from a larger dataset, conducted after the decision from Biogen to discontinue aducanumab after a flunked futility analysis in March 2019. Yesterday’s decision is, in our view, overall supportive of the amyloid-β hypothesis.